CorriX

CorriX is the world's first Nutraceutical with anti-cancer immune surveillance function.Taking Corix increases the level of TF-α antibody in the body, and this increased TF-α antibody binds to the TF-α antigen of cancer cells and activates the immune system that kills cancer cells. The level of TF-α antibody in the human body varies from person to person, and studies have shown that the lower the level of TF-α antibody, the higher the incidence of cancer. Therefore, it is very important to maintain an adequate level of TF-α antibody for a healthy immune system.CorriX is the world's first nutraceutical with anti-cancer immune surveillance function and its effectiveness has been proven through clinical trials involving 140 people in Germany.CorriX has been patented in 32 countries around the world, including the US and EU, and its safety has been proven by US FDA GRAS and EU esfa novel food certification.